Becton Dickinson gets its spinoff deal, but the stock is still falling

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.

Previous Article

You can keep buying non-U.S. stocks and ditching the dollar — or you can be smart

Next Article

Trump’s copper tariff is a first step. Here’s what’s needed now to counter China.

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *

Subscribe to our Newsletter

Subscribe to our email newsletter to get the latest posts delivered right to your email.
Pure inspiration, zero spam ✨